Brain disease drug trial halted after offering continued treatment
NCT ID NCT06111014
Summary
This study aimed to provide continued access to the experimental drug latozinemab for people with neurodegenerative brain diseases who had already taken it in a previous trial. It was designed to monitor the safety of longer-term treatment. The study was terminated and only enrolled 17 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEURODEGENERATIVE DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda Ospedaliero Universitaria Di Modena Policlinico
Modena, 41126, Italy
-
Centro Hospitalar E Universitario de Coimbra EPE
Coimbra, 3000-075, Portugal
-
Centro Hospitalar Universitário Lisboa Norte, EPE - Hospital de Santa Maria
Lisbon, 1649-028, Portugal
-
Dignity Health - Arizona
Phoenix, Arizona, 85013, United States
-
Erasmus MC-Dr. Molewaterplein 40
Rotterdam, 3015 GD, Netherlands
-
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico -Via Fracesco Sforza 35
Milan, 20122, Italy
-
Groupe Hospitalier Pitié Salpétrière
Paris, 75013, France
-
IRCCS - Centro S. Giovanni di Dio Fatebenefratelli
Brescia, 25125, Italy
-
Irving Institute for Clinical and Translational Research
New York, New York, 10032, United States
-
Karolinska Universitetssjukhuset Huddinge
Huddinge, SE-14186, Sweden
-
Mayo Comprehensive Cancer Center - PPDS
Rochester, Minnesota, 55905, United States
-
Parkwood Institute
London, Ontario, N6C 0A7, Canada
-
Sunnybrook Health Sciences Centre
Toronto, Ontario, M4N 3M5, Canada
-
UZ Leuven
Leuven, 3000, Belgium
-
University College London
London, WC1NAR, United Kingdom
-
University of Cincinnati Gardner Neuroscience Institute
Cincinnati, Ohio, 45219, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Universitätsklinikum Ulm - Leimgrubenweg 12-14
Ulm, 89075, Germany
Conditions
Explore the condition pages connected to this study.